A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy

被引：58

作者：

Jiang, Guan ^{[1
,2
,3
]}

Wei, Zhi-Ping ^{[1
]}

Pei, Dong-Sheng ^{[2
]}

Xin, Yong ^{[2
]}

Liu, Yan-Qun ^{[1
]}

Zheng, Jun-Nian ^{[2
]}

机构：

[1] Xuzhou Med Coll, Affiliated Hosp, Dept Dermatol, Xuzhou 221002, Peoples R China

[2] Xuzhou Med Coll, Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China

[3] Ctr Dis Control & Prevent Xuzhou City, Xuzhou 221006, Peoples R China

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2011年 / 406卷 / 03期

关键词：

Glioma; Melanoma; Gene therapy; TMZ; MGMT; Conditionally-replicating adenoviruses; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE; PHASE-II TRIAL; METASTATIC MELANOMA; IFN-BETA; ANTITUMOR-ACTIVITY; DOWN-REGULATION; DNA METHYLTRANSFERASE; RNA INTERFERENCE; CELLS RESPONSE; CANCER;

D O I：

10.1016/j.bbrc.2011.02.042

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Malignant glioma is the most common primary brain tumor. Malignant melanoma is the most malignant of skin tumor. The two malignancies are poorly responsive to conventional treatment regimens such as chemotherapy. Temozolomide (TMZ) is a DNA-alkylating agent used for the treatment of glioma, astrocytoma, and melanoma. Resistance to alkylating agents such as TMZ correlates with increased expression of DNA repair protein 06-methylguanine-DNA methyltransferase (MGMT). Several studies in animal models have demonstrated that decreasing MGMT level with gene therapy could overcome TMZ resistance and enhance tumor cell death. In the present review, we provide an overview of recent advances in this field. (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：311 / 314

页数：4

共 46 条

[1]

Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter [J].